TCL Archive NCI Outlines Need For $3,873 Billion To Seize Cancer Research Opportunities October 30, 1998
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
TCL Archive House Preserves Funds For Space Station; Cancer Societies Reiterate Support For $170 Million Increase For NCI August 7, 1992
TCL Archive In Brief: Kennedy Drops Health Care Institute Plan Senate Approves Dole Amendment On Patents August 18, 1978
TCL Archive Varmus: NCI Needs To Rethink, Review; Programs Must Be “At A High Level” November 12, 2010
